Related Experiment Video
Updated: Feb 24, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient
Jay Pravin Patel1,2, Eric Hweegeun Lee1,2, Carlos Ignacio Mena-Hurtado3
1Yale School of Medicine, PO Box 208058, New Haven, CT, 06520-8058, USA.
Insights
Hypertension and erectile dysfunction often coexist. For hypertensive men with erectile dysfunction, consider angiotensin-receptor blockers, ACE inhibitors, or calcium channel blockers, with PDE-5 inhibitors as a first-line treatment.
Area of Science:
- Cardiovascular Medicine
- Urology
- Pharmacology
Background:
- Hypertension and erectile dysfunction (ED) prevalence are rising, with over 40% of men with ED also diagnosed with hypertension.
- Managing patients with both conditions presents a clinical challenge due to their correlation and shared risk factors.
- A knowledge gap exists among clinicians regarding the diagnosis and treatment of ED in hypertensive patients.
Purpose of the Study:
- To review current literature on diagnosing and treating ED in hypertensive patients.
- To provide clinical recommendations for managing this patient population.
- To address the complexities of co-occurring hypertension and ED.
Main Methods:
- Literature review of current research on hypertension and erectile dysfunction.
- Analysis of pharmacological treatments for hypertension and their impact on sexual function.
- Evaluation of treatment guidelines for erectile dysfunction in hypertensive individuals.
Main Results:
- Antihypertensive medications can negatively impact sexual function; some ED treatments are contraindicated with specific antihypertensives.
- Recommended hypertension treatments for men with ED include angiotensin-receptor blockers, followed by angiotensin-converting enzyme inhibitors or calcium channel blockers.
- Phosphodiesterase type 5 (PDE-5) inhibitors are the first-line treatment for ED, but cardiovascular fitness for sexual activity must be assessed.
Conclusions:
- Careful selection of antihypertensive agents is crucial to avoid adverse effects on sexual function.
- Angiotensin-receptor blockers, ACE inhibitors, and calcium channel blockers are preferred for hypertension in men with ED.
- PDE-5 inhibitors are effective for ED, necessitating a prior cardiovascular assessment.
Purpose Of Review:
The prevalence of hypertension and erectile dysfunction has steadily increased, and greater than 40% of men with erectile dysfunction concurrently share a diagnosis of hypertension. The treatment of the patient with both diseases poses a clinical challenge as both are closely correlated and share multiple overlapping risk factors.To address the recognized knowledge gap among clinicians who care for these patients, we will review the current literature on the diagnosis and treatment of erectile dysfunction in the hypertensive patient and will provide recommendations for the management of this challenging patient population.
Recent Findings:
The pharmacological treatment of hypertension may adversely affect sexual function, and certain treatments for erectile dysfunction are contraindicated or cautioned against with certain antihypertensive agents. In review of the literature, we find that the clinician should opt to use an angiotensin-receptor blocker followed by an angiotensin-converting enzyme inhibitor or calcium channel blocker for the treatment of hypertension in patients with erectile dysfunction. Other agents require careful consideration for adverse effects on sexual function. Men with erectile dysfunction should be assessed for cardiovascular fitness for sexual activity, and PDE-5 inhibitors remain the first-line treatment for erectile dysfunction.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension and Regulation of Blood Pressure

